Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients The POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MSc

First Page		Document Content
Date: 2014-09-10 10:15:50 Organic chemistry Ketones Oncology 5-HT3 antagonist Drug discovery Chemotherapy Ondansetron Aprepitant Methadone Medicine Chemistry Antiemetics		Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients The POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MSc Add to Reading List Source URL: www.pogo.ca Download Document from Source Website File Size: 2,60 MB Share Document on Facebook

	P11444 - ASCO2014 MEC and HEC DocID: 1a4Ek - View Document
	P11444 - ASCO2014 MEC and HEC DocID: 19OCx - View Document
	Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella DocID: 19AF1 - View Document
	P11444 - ASCO2014 MEC and HEC DocID: 199Dl - View Document
	P11444 - ASCO2014 MEC and HEC DocID: 1987o - View Document